Bupropion: a review of its mechanism of antidepressant activity.
about
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XLA Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake InhibitorAnimal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletionsMolecular genetics of successful smoking cessation: convergent genome-wide association study resultsRomantic love: a mammalian brain system for mate choiceTobacco Use Cessation and Prevention - A ReviewBacoside A: Role in Cigarette Smoking Induced Changes in BrainReward-Induced Eating: Therapeutic Approaches to Addressing Food CravingsDes-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transportersPharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawalDiminished conditioned responding to the nicotine stimulus by antidepressant drugs with differing specificity for the serotonin and norepinephrine transporter.Emergence of anxiety-like behaviours in depressive-like Cpe(fat/fat) miceBupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.Sex heterogeneity in pharmacogenetic smoking cessation clinical trialsIndolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine releasePsychological mediators of bupropion sustained-release treatment for smoking cessationCo-morbidity of smoking in patients with psychiatric and substance use disorders.Bupropion decreases resting motor threshold: a case report.Bupropion differentially impacts acquisition of methamphetamine self-administration and sucrose-maintained behavior.Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET studyPavlovian drug discrimination with bupropion as a feature positive occasion setter: substitution by methamphetamine and nicotine, but not cocaine.Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for Tobacco DependenceDopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitorsMicroinfusion of bupropion inhibits putative GABAergic neuronal activity of the ventral tegmental area.The Effect of Acute Intra Locus Coeruleus (LC) Microinfusion of Bupropion on Formalin-Induced Pain Behavior in Rat.Efficacy of bupropion alone and in combination with nicotine gum.The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors.Neonatal pain and COMT Val158Met genotype in relation to serotonin transporter (SLC6A4) promoter methylation in very preterm children at school age.The use of bupropion SR in cigarette smoking cessationSmoking cessation therapy with vareniclineGenetic influences on smoking: candidate genes.Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled studyRecent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior.The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.
P2860
Q21093304-1BEDCF9F-E969-4E7A-B54C-E8989C513973Q24530904-F77689E9-2AEC-484A-9A9E-396F43CD9F85Q24563250-E046E59A-A56D-4775-97ED-451BC2B9F2B2Q24651067-8D2F69DC-104B-434D-A0E5-E7217CD5CCCBQ24653819-B503C266-AAD4-456E-AAD5-193C2CA2DB8BQ24675930-A434C052-5C8C-436D-A7B7-07D1E760AFA1Q26738823-76A87B5B-A42F-418D-80A8-9C37D2A6B7D8Q26786019-E94693A3-0794-4849-9E1D-EE03B4CAD5C0Q28074195-35B5918C-2714-47CE-887D-585F7D4A43E5Q28257395-CBE41B1E-DF10-47F9-88BA-9DC1FBB75291Q28545209-0B3C71E5-5BFB-485C-932D-AD17DCCD7FD1Q30433175-273709DC-A758-44C5-9E64-38D3084DB342Q30459642-13352C07-3AC4-4CA6-A4A0-FACEACAB2F5FQ30562163-B1F77CAD-F367-4724-AD4F-F4BB538CD040Q31138857-9A5D7C8B-83E4-408B-BB3C-223C458B8EBDQ33449522-9C9F7565-E7A2-4BBD-91FB-0574779C92ABQ33582051-2B9D40EA-F927-436D-82C4-19CB73DFD2B5Q33605769-8DA0266E-6879-44A4-BC9F-CAEDDAC9A893Q33836376-67DCA1D3-CA12-4AF3-B752-9C2595A9CCB6Q33887773-4E61BD3B-B13D-4344-840C-DBB003ECA904Q33942653-BA0923F9-BCEB-44E5-93E4-D478667CE716Q34001632-004DCC8D-B07D-4DD8-A2B0-FBF65CDFFA70Q34044560-BE491ADD-71B7-4385-905A-83439B018E79Q34054242-C7813F6D-A263-467F-87EB-25AC096DA415Q34060576-C87CDA40-FE7A-4364-B7FB-5FB4BA244693Q34164210-FC98BE39-E782-43D1-BCB7-C022C483B3E8Q34311649-936BF872-6F86-4277-8C0C-C4AAD64EAE18Q34321467-AAE858F9-D4CB-45CC-A631-0CAA67BF43A3Q34367958-D9412C6A-06FD-4E4B-AB20-0D4D04BB3224Q34368165-25ED994F-2DF7-43A0-84CA-F47F180C2A4AQ34535754-51F5D7E3-ABDD-4924-A8C5-F7D71A09E89EQ34541188-70EFB145-1359-4E7B-822A-4BE7CF0FE146Q34608922-B7B966E9-8062-43EB-B956-06B756C93D43Q34779470-D4B390A3-0EEE-447E-898C-0414028859FDQ34805380-8CFAB59B-37E1-4665-B56F-6D282C122A4DQ34938233-9FAC8B8C-5955-4711-BE42-537BCF66EE9FQ35054544-094CFF10-BB10-49C1-9935-E19E477EC982Q35124169-90F5D461-3563-4322-9DC7-FEABABC8F3B3Q35184641-851E3796-7713-4CBF-8089-CEB2AD551ED6Q35532003-37725C6B-0133-4F68-A616-44983816D188
P2860
Bupropion: a review of its mechanism of antidepressant activity.
description
1995 nî lūn-bûn
@nan
1995 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Bupropion: a review of its mechanism of antidepressant activity.
@ast
Bupropion: a review of its mechanism of antidepressant activity.
@en
Bupropion: a review of its mechanism of antidepressant activity.
@nl
type
label
Bupropion: a review of its mechanism of antidepressant activity.
@ast
Bupropion: a review of its mechanism of antidepressant activity.
@en
Bupropion: a review of its mechanism of antidepressant activity.
@nl
prefLabel
Bupropion: a review of its mechanism of antidepressant activity.
@ast
Bupropion: a review of its mechanism of antidepressant activity.
@en
Bupropion: a review of its mechanism of antidepressant activity.
@nl
P2093
P1476
Bupropion: a review of its mechanism of antidepressant activity
@en
P2093
Feighner JP
Fibiger HC
Richelson E
P304
P577
1995-09-01T00:00:00Z